UK pharma negotiating choppy seas during Brexit

UK pharma negotiating choppy seas during Brexit


Article courtesy of Richard Staines Pharmaphorum

In an interview with Pharmaphorum, Erik Nordkamp, the outgoing president of the Association of the British Pharmaceutical Industry (ABPI), tells pharmaphorum how UK pharma is plotting its way through the chaos of Brexit, while creating a vision for the future of the country’s life sciences industry sector with its new pricing deal for branded drugs.

The ABPI is working closely with the Department of Health and Social Care, NHS England and NICE to evolve the market access environment to improve access to new medicines for UK patients.

Read the full interview here

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.